ArticleNucleic acids research2013
STAT1:DNA sequence-dependent binding modulation by phosphorylation, protein:protein interactions and small-molecule inhibition.
Article in Nucleic acids research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Integrated Evolutionary and Multi-Omic Analysis of STAT Family Activation Across Solid Tumors.Genes · 2026Article
- Malignant JAK-signaling: at the interface of inflammation and malignant transformation.Leukemia · 2025Review
- Polyphenol Profile and Antioxidant, Antityrosinase, and Anti-Melanogenesis Activities of Ethanol Extract of Bee Pollen.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Inhibition of complement C3 prevents osteoarthritis progression in guinea pigs by blocking STAT1 activation.Communications biology · 2024Article
- Kinetics of cytokine receptor trafficking determine signaling and functional selectivity.eLife · 2019Article
- Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis.Theranostics · 2019Review
- Quantitative specificity of STAT1 and several variants.Nucleic acids research · 2017Article
- Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease.Oncotarget · 2016Review
- Dry and wet approaches for genome-wide functional annotation of conventional and unconventional transcriptional activators.Computational and structural biotechnology journal · 2016Review
- Chromatin variation associated with liver metabolism is mediated by transposable elements.Epigenetics & chromatin · 2016Article
- Targeting RNA polymerase I to treat MYC-driven cancer.Oncogene · 2015Review
- Using protein-binding microarrays to study transcription factor specificity: homologs, isoforms and complexes.Briefings in functional genomics · 2015Review
- Article
- STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling.Nature immunology · 2014Article
- Computational models of the JAK1/2-STAT1 signaling.JAK-STAT · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The DNA-binding specificity and affinity of the dimeric human transcription factor (TF) STAT1, were assessed by total internal reflectance fluorescence protein-binding microarrays (TIRF-PBM) to evaluate the effects of protein phosphorylation, higher-order polymerization and small-molecule inhibition. Active, phosphorylated STAT1 showed binding preferences consistent with prior characterization, whereas unphosphorylated STAT1 showed a weak-binding preference for one-half of the GAS consensus site, consistent with recent models of STAT1 structure and function in response to phosphorylation. This altered-binding preference was further tested by use of the inhibitor LLL3, which we show to disrupt STAT1 binding in a sequence-dependent fashion. To determine if this sequence-dependence is specific to STAT1 and not a general feature of human TF biology, the TF Myc/Max was analysed and tested with the inhibitor Mycro3. Myc/Max inhibition by Mycro3 is sequence independent, suggesting that the sequence-dependent inhibition of STAT1 may be specific to this system and a useful target for future inhibitor design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.